Life Science Dealmakers Gather in Shanghai, China, April 15

公司 每日财经网

Carlsbad, CA and Shanghai, China – April 6, 2015: Internationally-focused life science executives and investors will converge upon Shanghai, China this April 15–16 for the ChinaBio® Partnering Forum 2015 (www.CBPF2015.com). The event is China’s premier life science partnering event, and dealmakers attend with the goal of establishing cross-border partnerships to access China’s rapidly growing healthcare market.

The event program is targeted toward dealmaking in the life sciences, and kicks off on Tuesday, April 14 with a Partnering Bootcamp called “How to partner with global pharma,” followed by the Welcome Reception at Kerry Hotel Pudong where the event will be held.

The next two days feature intensive one-to-one partnering facilitated by partneringONE®, and program panels covering topics from structuring deals to China’s innovation in biologics. Shanghai is the center of China’s pharmaceutical and biotech industry with over 1,000 life science companies, many involved in cross-border partnerships with Western companies.

Notable speakers on the program include:

  • Ruediger Hermann – Partner, Dechert LLP
  • Yuliang Huang, PhD – CEO, Generon (Shanghai) Corporation Ltd.
  • Judith Li, MBA – Principal, Lilly Asia Ventures
  • Scott Liu, PhD – President and CEO, Henlius Biotech Co., Ltd.
  • Mark G. Lotter, MBA – Founder and CEO, Nuance Biotech Inc.
  • Peter Luo, PhD – Founder and CEO, Adagene (Suzhou) Limited
  • Mark Noguchi – VP and Global Head, Alliance and Asset Management, Roche Partnering
  • Greg Scott – Founder and Chairman, ChinaBio® Group
  • Jonathan Wang, PhD, MBA – Senior Managing Director, OrbiMed Asia
  • Mingde Xia, PhD – Senior Director, Johnson & Johnson Innovation
  • Steve Yang, PhD – Executive VP and COO, WuXi AppTec
  • Michael Yu, PhD – President and CEO, Innovent Biologics, Inc.
  • Joe Zhou, PhD – CEO, GenorBioPharma and VP, Walvax Group

This year, a record 50 innovative companies, organizations and researchers will be presenting their technologies or products in order to initiate strategic alliances at ChinaBio® Partnering Forum. A complete list can be found on the Presenting Companies web page (see www.ebdgroup.com/cbpf/presenters/prs_comps.php).

Registration information can also be found online at www.ebdgroup.com/cbpf/registration. There is a reduced registration fee for China-based organizations.

# # #

About ChinaBio® Group:

Since its founding in 2007, ChinaBio® Group has created a broad platform of capabilities connecting China life science with the world. ChinaBio has helped western life science companies identify over 1,000 licensing and acquisition opportunities and raise over USD 500 million in funding in China.

  • Conferences: ChinaBio organizes the premier life science investment and partnering conferences in China, having attracted over 5,000 attendees.
  • Consulting: ChinaBio helps global life science companies to define and execute a successful strategy in China.
  • Capital: ChinaBio launched its first VC fund in 2014 focused on bringing Western companies and technologies to China.
  • Publishing: ChinaBio®Today is the most widely read online and email newsletter on China's life science industry, with over 20,000 readers.

More information is available at www.chinabio.com.

Contact:

Jean Meng

ChinaBio® Group

780 Cailun Road, #822

Shanghai 201203 China

From China: +86 21 5137 0751

From USA: +1 858 859 1860

Jean.Meng@chinabio.com

About EBD Group

EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group’s partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success.

EBD Group’s conferences are run with the support of leading corporations and international trade associations and include:

  • BIO-Europe® and BIO-Europe Spring®, Europe’s largest life science partnering conferences, supported by the Biotechnology Industry Organization (BIO)
  • BioPharm America™, the fastest growing partnering event in North America
  • Biotech Showcase™, a unique forum in San Francisco for presenting to investors and business development executives, co-produced with Demy-Colton Life Science Advisors
  • BioEquity Europe, the investor conference co-organized with BioCentury Publications and BIO
  • ChinaBio® Partnering Forum, the first dedicated biotech/pharma partnering conference in China, co-produced with ChinaBio® LLC
  • Medtech Partnering Forum, EBD Group’s partnering event for the innovative medical technology industry, will be the first dedicated medtech partnering conference in Japan
  • Biolatam®,facilitating partnering among global life sciences executives in Latin America’s vibrant life science hubs
  • The Global Impact Forum™, a unique and innovative partnering conference in impact investing and venture philanthropy.

EBD Group’s sophisticated web-based partnering service, partneringONE®, is used as the partnering engine at numerous third-party events around the world, andpartnering360® is the open online community of life science dealmakers that enhances partnering experiences throughout the year.

EBD Group is an Informa company. Informa is the largest publicly-owned organizer of exhibitions, conferences and training in the world.

EBD Group has offices in the USA and Europe.

For more information please visit www.ebdgroup.com.

Contact:

Erin Righetti

EBD Group

+1 760 930 0500

erighetti@ebdgroup.com

SpinalCyte在China Focus @ Europe Vienna上进行呈报

CHINA的待客之道:华光华青瓷惊艳亮相青岛上合国宴

2018年第二届中国保险科技创新国际峰会(2nd InsurTech China 2018)将于9月12-14日在上海召开

✽本文资讯仅供参考,并不构成投资或采购等决策建议(BW)。

The EXNESS team attended the Shanghai Grand Prix this weekend and met with its partners to discuss further cooperation.
  • 公司
  • 2015-4-14
  • 每日财经网
4月25日,北京车展开幕首日,梅赛德斯-奔驰宣布与腾讯和艺电合作,将首款开放世界赛车手游《极品飞车™:集结》引入中国市场。此款游戏计划通过OTA搭载在配备第三代MBUX智能人机交互系统的梅赛德斯-奔驰车辆上。 《极品飞车™:集结》由腾讯天美…
  • 汽车
  • 5小时前
  • 每日财经网
中信证券1月31日发布评级报告,首次覆盖中烟香港,给予“买入”评级。报告称,鉴于公司独家经营的市场地位、业绩高确定性和标的稀缺性,综合DCF 模型及相对估值,判断公司合理市值为约87亿港元,目标价13港元,对应2024年15xPE。 研报指…
  • 公司
  • 2月1日
  • 每日财经网